Antibe Therapeutics Inc
TSX:ATE

Watchlist Manager
Antibe Therapeutics Inc Logo
Antibe Therapeutics Inc
TSX:ATE
Watchlist
Price: 0.295 CAD Market Closed
Market Cap: 4.7m CAD

Intrinsic Value

There is not enough data to reliably calculate the intrinsic value of ATE.

The Intrinsic Value is calculated as the average of DCF and Relative values:

ATE Intrinsic Value
Not Available
Base Case Scenario
Compare ATE to

Fundamental Analysis

Antibe Therapeutics Inc
TSX:ATE
CA
Pharmaceuticals
Market Cap
4.7m CAD
IPO
Jun 18, 2013
CA
Pharmaceuticals
Market Cap
4.7m CAD
IPO
Jun 18, 2013
Price
CA$false
EPS
CA$false
Company Overview
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about ATE?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about Antibe Therapeutics Inc
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
Antibe Therapeutics Inc

Current Assets 31.1m
Cash & Short-Term Investments 27.8m
Receivables 1.6m
Other Current Assets 1.7m
Non-Current Assets 29.1m
Intangibles 26.4m
Other Non-Current Assets 2.7m
Efficiency

Free Cash Flow Analysis
Antibe Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Antibe Therapeutics Inc

Revenue
0 CAD
Operating Expenses
-20m CAD
Operating Income
-20m CAD
Other Expenses
1.3m CAD
Net Income
-18.7m CAD
Fundamental Scores

ATE Profitability Score
Profitability Due Diligence

Antibe Therapeutics Inc's profitability score is 25/100. The higher the profitability score, the more profitable the company is.

ROIC is Increasing
Low 3Y Average Gross Margin
Declining ROE
Negative 3Y Average Net Margin
25/100
Profitability
Score

Antibe Therapeutics Inc's profitability score is 25/100. The higher the profitability score, the more profitable the company is.

ATE Solvency Score
Solvency Due Diligence

Antibe Therapeutics Inc's solvency score is 56/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Low D/E
Long-Term Solvency
Low Altman Z-Score
56/100
Solvency
Score

Antibe Therapeutics Inc's solvency score is 56/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ATE Price Targets Summary
Antibe Therapeutics Inc

There are no price targets for ATE.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Dividends

Antibe Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for ATE is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y